Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study…
<!-- Name:DistributionId Value:8741606 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Axitinib
Pre-Op Axitinib Helps for Partial Nephrectomy of Complex Renal Tumors
SAN DIEGO -- Use of neoadjuvant axitinib (Inlyta) resulted in significant reductions in tumor size and complexity, enabling…
Axitinib Intravitreal Implant Shows Promise for Wet AMD
At the American Academy of Ophthalmology (AAO) annual meeting, new data were presented from a 7-month…
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX…
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a…
Clinical Challenges: First-Line Options for Metastatic RCC
Fifteen years ago, the average patient who walked into an oncology clinic with metastatic renal…
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a…
ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore…